Clinical Trial

Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

Study acronym: DeLLight
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2 single-arm, open-label clinical trial designed to evaluate the efficacy and safety of tarlatamab in patients with relapsed extrapulmonary neuroendocrine carcinoma (EPNEC) who have previously received platinum-based first-line chemotherapy. Participants will receive tarlatamab on Cycle 1 Day 1 (C1D1), Day 8 (C1D8), and Day 15 (C1D15), followed by administration every two weeks thereafter. No placebo control is included in this study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-18; most recent amendment 2026-04-09.
Status change: Not Yet Recruiting → Recruiting 2025-09-02
Trial Details
NCT Number NCT06893783
Lead Sponsor Inkeun Park
Collaborators: Seoul National University Hospital, Severance Hospital, Samsung Medical Center
Conditions Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas, Neuroendocrine Carcinoma of Prostate
Enrollment 60 participants
Start Date 2025-09-02
Primary Completion 2029-04-30 (estimated)
Study Completion 2029-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-13